(Hypertension. 1999;33:1153-1158.)
© 1999 American Heart Association, Inc.
Scientific Contributions |
From the Cardiovascular Division, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City.
Correspondence to Virend Somers, MD, PhD, Cardiovascular Division, Department of Internal Medicine, University of Iowa, 200 Hawkins Dr, Iowa City, IA 52242. E-mail virend-somers{at}uiowa.edu
| Abstract |
|---|
|
|
|---|
Key Words: hypercapnia hypoxia chemoreceptors sympathetic nervous system obesity
| Introduction |
|---|
|
|
|---|
E) inhibits the sympathetic response to chemoreflex
activation.9 10 Obesity is associated with an increased risk of alveolar hypoventilation and CO2 retention,11 12 suggesting that chemoreflex control mechanisms may be disturbed. Surprisingly, the effect of obesity on chemoreflex function has received relatively little attention. Previous studies examining chemoreflex function in obese subjects have examined primarily the ventilatory responses. These studies have reported conflicting results, showing either increased,13 14 decreased,15 or normal16 17 responsiveness to hypoxia in obese subjects. Conflicting results have also been reported in studies examining responses to hypercapnia. Obese subjects have been shown to have either increased14 17 or decreased13 15 18 ventilatory responses to hypercapnia. Ventilatory responsiveness to hypercapnia is reduced by weight loss19 20 and increased by abdominal mass loading,21 suggesting that obesity might be associated with potentiated central chemoreflex sensitivity. Sympathetic responses to hypoxia or hypercapnia in obese subjects have not been previously studied.
Discrepancies in the results of earlier studies might be explained by a number of factors. First, some of the studies reporting decreased central chemoreflex sensitivity in obesity included hypercapnic subjects with obesity-hypoventilation syndrome.15 18 Thus, findings of decreased central chemosensitivity in patients with chronically elevated arterial CO2 levels may represent an adaptation to hypercapnia. Second, chemoreflex sensitivity is significantly influenced by age,22 23 24 gender,14 and hypertension.6 25 Hence, the absence of control for these variables may be implicated in the lack of consistency in earlier studies. Third, even asymptomatic obese individuals have a high incidence of occult obstructive sleep apnea,26 which may itself be accompanied by abnormalities in chemoreflex function.27 28 Thus, undiagnosed sleep apnea in apparently normal obese subjects may obscure any distinctive chemoreflex abnormalities associated with obesity per se.
We tested the hypothesis that chemoreflex function is altered in obesity, independent of such factors as age, gender, hypertension, and occult sleep apnea. We measured ventilatory, autonomic, and hemodynamic responses to peripheral chemoreceptor activation by hypoxia and to central chemoreceptor activation by hypercapnia in obese subjects, in whom occult sleep apnea was excluded by complete overnight polysomnographic study. These responses were compared with those obtained in normal-weight subjects matched for age and gender. To ensure that any abnormalities in chemoreflex function were specific to the chemoreflexes and did not represent a generalized abnormality in response to excitatory stimuli, we also compared responses to the cold pressor test (CPT), which served as an internal control.29 30
| Methods |
|---|
|
|
|---|
24 kg/m2 for women and
25
kg/m2 for men.31 The mean BMI was
35±2 kg/m2 for obese subjects and 23±1
kg/m2 for normal-weight subjects. None of the
subjects was taking any medications or had any chronic disease. Occult
obstructive sleep apnea in obese subjects was ruled out by complete
overnight polysomnographic study, including electroencephalography,
electromyography, electro-oculography,
electrocardiography, chest wall movement, nasal
and oral air flow, and oxygen saturation. Informed written consent was
obtained from all subjects. The study was approved by the institutional
Human Subjects Review Committee.
Measurements
Heart rate (HR) was measured continuously by an ECG. Blood
pressure was measured each minute by an automatic sphygmomanometer
(Life Stat 200, Physio-Control Corp). Oxygen saturation was monitored
with a pulse oximeter (Nellcor Inc). End-tidal
CO2 was monitored using a Hewlett-Packard 47210A
Capnometer.
E was determined using a KL Engineering
S430 monitor. Subjects breathed through a mouthpiece with a nose clip
to ensure exclusive mouth breathing. Sympathetic nerve activity to
muscle (MSNA) was recorded continuously by obtaining multiunit
recordings of postganglionic sympathetic activity to muscle
blood vessels, measured from a muscle nerve fascicle in the peroneal
nerve posterior to the fibular head as described
previously.32
Protocol and Procedures
Subjects were studied in the supine position. The protocol used
to determine chemoreflex responses to isocapnic hypoxia and
hyperoxic hypercapnia was identical to that used in previous
studies.9 10 33 Subjects were exposed to a hypoxic gas
mixture to induce peripheral chemoreflex activation (10%
O2 in N2 with
CO2 titrated to maintain isocapnia) and to a
hypercapnic gas mixture to induce central chemoreflex activation (7%
CO2 and 93% O2). During
hypoxic stimulation of peripheral chemoreceptors,
perturbation of central chemoreceptors was minimized by
maintenance of isocapnia.10 During hypercapnic
stimulation of central chemoreceptors, perturbation of
peripheral chemoreceptors was minimized by
hyperoxia.9 The sequence of hypoxic and hypercapnic
interventions was randomized. At least 15 minutes separated the end of
one intervention from the beginning of the next.
Baseline measurements were taken during a 5-minute period of stable ventilation while subjects breathed room air with a mouthpiece. Then, with use of a 3-way valve, subjects were exposed to either hypoxic or hypercapnic stressors for 3 minutes. Average values for the 3-minute period of gas exposure were compared with measurements obtained at baseline. At the end of the hypoxic and hypercapnic exposures, subjects underwent a brief period of voluntary end-expiratory apnea (10 to 15 seconds) to examine the sympathetic responses to chemoreflex activation in the absence of the inhibitory influence of the thoracic afferents. We were not able to obtain stable nerve recordings in 2 subjects (1 obese and 1 normal-weight subject). Consequently, sympathetic responses to hypoxia and hypercapnia were obtained in 13 overweight and 13 normal-weight subjects. Twelve overweight and 13 normal-weight subjects underwent a subsequent CPT. The CPT is a stimulus for ventilation and sympathetic excitation and involves immersing the subject's hand in ice water for 2 minutes.29 30
Analyses
Sympathetic bursts were identified by careful inspection of the
voltage neurogram. The amplitude of each burst was determined, and
sympathetic activity was calculated as bursts per minute multiplied by
mean burst amplitude and expressed as units per minute. Measurement of
nerve activity at baseline before each intervention was expressed as
100%. For the apneas, the first 10 seconds was analyzed,
because all subjects were able to maintain apnea for at least 10
seconds at the end of both the hypoxic and hypercapnic exposures.
Changes in sympathetic nerve activity were expressed as the percentage
of increase from the preceding minute (eg, last minute of
hypoxia or hypercapnia).
Changes in integrated MSNA allow evaluation of within-subject changes in sympathetic traffic during the same recording session. Sympathetic activity was also expressed as bursts per minute, which allows comparison of sympathetic discharge between individuals, thus permitting a comparison of MSNA between obese and normal-weight subjects. Demographic data and baseline characteristics were compared using an unpaired t test. Responses to hypoxia, hypercapnia, and the CPT were analyzed by repeated-measures ANOVA with time (baseline versus intervention) as within factor and group (obese versus normal-weight subjects) as between factor. The key variable was the group-by-time interaction. Data are mean±SEM. P<0.05 was considered significant.
| Results |
|---|
|
|
|---|
|
Responses to Hypercapnia
The baseline levels and increases of end-tidal
CO2 during hypercapnia were similar in
normal-weight and obese subjects (Table 2
and Figure 1). During hypercapnia, HR did
not change significantly in either normal-weight or obese subjects
(Table 2). Both normal-weight and obese subjects had increases
in
E, blood pressure, and MSNA during hypercapnia.
However, the increase in
E during hypercapnia was
significantly greater in obese subjects (Table 2 and Figure 1) (P<0.04).
|
|
Despite higher
E values during hypercapnia in obese
subjects, the percentage increases in MSNA during hypercapnia were
similar in obese and normal-weight subjects (Table 2 and Figure 1). When the inhibitory influence of breathing
during hypercapnia was eliminated by apnea, the increase in MSNA in
obese subjects was greater than in normal-weight subjects (Figure 2). MSNA during apnea increased by
99±16% in obese subjects and by 44±16% in normal-weight subjects
(P=0.02).
|
Responses to Hypoxia
The magnitude of the ventilatory, HR, blood pressure, and MSNA
responses to hypoxia was similar in obese and normal-weight
subjects (Table 3 and Figure 1).
Changes in MSNA in response to apnea during hypoxia were also
similar in the 2 groups (69±21% in obese subjects and 83±26% in
normal-weight subjects).
|
Effects of CPT
Autonomic, ventilatory, and blood pressure changes during the CPT
in obese subjects were not significantly different from those observed
in normal-weight subjects (Table 4).
|
| Discussion |
|---|
|
|
|---|
Previous studies have reported conflicting results regarding central chemoreflex function in obesity, with some studies reporting decreased,13 15 18 normal,16 or increased14 17 ventilatory responses to hypercapnia in obese subjects. Aging is associated with blunting of the ventilatory responses to hypercapnia.22 24 In 1 study reporting a decreased hypercapnic ventilatory response in obesity,13 obese subjects were older than normal-weight subjects. Moreover, most of the obese subjects were women, whereas all the normal-weight control subjects were men. Thus, differences in age and gender distribution between obese and normal-weight subjects may have confounded results of this study.
In the present study, hypercapnic breathing elicited greater ventilatory responses in obese subjects than in normal-weight subjects. Increased ventilation acts as a powerful restraint on the sympathetic response to chemoreflex stimulation.8 10 Nevertheless, the increase in sympathetic activity in our obese subjects during hypercapnia was still comparable to that seen in normal-weight subjects despite the higher ventilation. When the inhibitory influence of ventilation was eliminated by apnea, the enhanced sympathetic response to hypercapnia was manifest. Thus, potentiation of the central chemoreflex response in obesity affects both the ventilatory and sympathetic efferent limbs of the reflex. Although increased ventilatory sensitivity might be beneficial in terms of preventing CO2 retention, potentiated sympathetic responsiveness might impose additional circulatory stress.
With respect to peripheral chemoreflex function in obesity, Kunitomo et al14 and Burki and Baker13 reported increased ventilatory responses to hypoxia in obese subjects. Interpretation of the former study is difficult, because a large proportion of the obese subjects had sleep-disordered breathing. The latter study did not address the potential influence of sleep apnea. Apparently normal obese subjects have a high prevalence of occult obstructive sleep apnea.26 Obstructive sleep apnea may itself be accompanied by a selective potentiation of the ventilatory response to hypoxia.28 Thus, the apparent potentiated peripheral chemoreflex sensitivity in obese subjects may be secondary to obstructive sleep apnea rather than a pathophysiological accompaniment of obesity per se.
Important strengths of this study are, first, that both ventilatory and sympathetic responses to hypercapnia, hypoxia, and the CPT were studied and that ventilatory and autonomic responses to hypercapnia alone were shown to be potentiated in the obese subjects. Thus, our findings suggest a selective chemoreflex abnormality in obesity and do not represent a nonspecific potentiation of responses to stressful stimuli. Second, all subjects were eucapnic and free of any disease, in particular, occult sleep apnea. Third, obese and normal-weight subjects were closely matched for gender, age, and blood pressure. Thus, the potential influence of these confounding variables was eliminated.
Potentiated central chemoreflex drive may serve as a protective mechanism maintaining eucapnia in the presence of an increased respiratory load. This hypothesis is consistent with data from an earlier uncontrolled study by Chapman et al,19 who reported that the hypercapnic ventilatory response decreased after weight loss in eucapnic obese subjects without sleep-disordered breathing. Eucapnic obese subjects have increased electromyographic responses of the diaphragm to hypercapnia.21 34 In contrast, electromyographic responses to hypercapnia in subjects with obesity-hypoventilation syndrome are decreased.34 The potentiated central chemoreflex drive evident in eucapnic obese subjects may become blunted in subjects who develop alveolar hypoventilation and CO2 retention, perhaps as a result of adaptation of the central chemoreflex to chronic hypercapnia. Alternatively, absence of potentiation of central chemoreflex in obesity may result in consequent progression to alveolar hypoventilation and CO2 retention.
Although the mechanism underlying the selective potentiation of the responses to hypercapnia is unknown, a recent study by Tankersley et al35 provides a rationale for hypothesizing that modulation of the central chemoreflex by leptin may be implicated. In studies in ob/ob mice, these investigators reported a marked impairment in ventilatory responses to hypercapnia.35 ob/ob mice are leptin deficient. In contrast, obese humans have markedly increased levels of leptin.36 We speculate that leptin may be important in modulation of the central chemoreflex so that, first, an absolute deficiency of leptin (in ob/ob mice) is accompanied by a blunted chemoreflex response to hypercapnia and, second, the increased leptin in obese humans is linked to a potentiated chemoreflex response to hypercapnia. We further speculate that the increased leptin in obese humans confers protection from obesity-related hypoventilation and hypercapnia and hence a possible survival advantage.
In conclusion, these data demonstrate a potentiation of ventilatory and sympathetic responses to hypercapnia in eucapnic obese subjects. In contrast, responses to hypoxia and responses to the excitatory cold pressor stimulus in obese subjects are similar to those in normal-weight subjects. Thus, obesity is characterized by selective potentiation of central chemoreflex sensitivity.
| Acknowledgments |
|---|
Received September 9, 1998; first decision October 22, 1998; accepted December 10, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
V. L Cooper, S. B Pearson, C. M Bowker, M. W Elliott, and R Hainsworth Interaction of chemoreceptor and baroreceptor reflexes by hypoxia and hypercapnia - a mechanism for promoting hypertension in obstructive sleep apnoea J. Physiol., October 15, 2005; 568(2): 677 - 687. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wolk, B. D. Johnson, and V. K. Somers Leptin and the ventilatory response to exercise in heart failure J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1644 - 1649. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. Trombetta, L. T. Batalha, M. U. P. B. Rondon, M. C. Laterza, F. H. S. Kuniyoshi, M. M. G. Gowdak, A. C. P. Barretto, A. Halpern, S. M. F. Villares, and C. E. Negrao Weight loss improves neurovascular and muscle metaboreflex control in obesity Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H974 - H982. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Saaresranta and O. Polo Sleep-disordered breathing and hormones Eur. Respir. J., July 1, 2003; 22(1): 161 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Negrao, I. C. Trombetta, L. T. Batalha, M. M. Ribeiro, M. U. P. B. Rondon, T. Tinucci, C. L. M. Forjaz, A. C. P. Barretto, A. Halpern, and S. M. F. Villares Muscle metaboreflex control is diminished in normotensive obese women Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H469 - H475. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |